GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PharmAust Ltd (ASX:PAA) » Definitions » Inventories, Finished Goods

PharmAust (ASX:PAA) Inventories, Finished Goods : A$0.00 Mil (As of Dec. 2023)


View and export this data going back to 2001. Start your Free Trial

What is PharmAust Inventories, Finished Goods?

PharmAust's annual finished goods increased from Jun. 2021 (A$0.95 Mil) to Jun. 2022 (A$0.97 Mil) but then declined from Jun. 2022 (A$0.97 Mil) to Jun. 2023 (A$0.00 Mil).


PharmAust Inventories, Finished Goods Historical Data

The historical data trend for PharmAust's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PharmAust Inventories, Finished Goods Chart

PharmAust Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Inventories, Finished Goods
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.61 0.86 0.95 0.97 -

PharmAust Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Inventories, Finished Goods Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.97 - - -

PharmAust Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.


PharmAust (ASX:PAA) Business Description

Industry
Traded in Other Exchanges
Address
1 Kyle Way, Suite 116, Claremont, Perth, WA, AUS, 6010
PharmAust Ltd operates as a drug discovery and development company in Australia, Switzerland, and internationally. It develops drug discovery intellectual property for the treatment of various cancers in humans and animals. The company offers Monepantel and Albendazole, which are in Phase II clinical trials for the treatment of cancer. It also provides medicinal and synthetic chemistry services on a contract basis to the drug discovery and pharmaceutical industries.